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Peritoneal elimination of homocysteine moieties in continuous In end-stage renal disease patients undergoing hemodial-
ambulatory peritoneal dialysis patients. ysis or peritoneal dialysis treatment, elevated plasma
Background. The amount of total homocysteine eliminated total homocysteine concentrations are frequently de-by peritoneal dialysis and its relationship to peritoneal trans-
tected [4, 5].port characteristics in continuous ambulatory peritoneal dial-
ysis (CAPD) patients are unknown. The major causes of hyperhomocysteinemia in uremic
Methods. The influence of total homocysteine, folate, and patients are the disturbance of the physiological homo-
vitamin B12 plasma concentrations, serum albumin levels, age, cysteine metabolism and the impairment of renal func-
sex, dialysate to plasma ratio (D/P) creatinine, D/D0 glucose, tion. Plasma total homocysteine concentrations haveD/P albumin, dialysate effluent volume, and effluent albumin
been shown to increase in parallel with the decline ofon the daily peritoneal excretion of total homocysteine was
investigated in 39 CAPD patients. The relationship of D/P the glomerular filtration rate [6]. Important additional
creatinine to D/P total homocysteine, D/P free homocysteine, predictors of hyperhomocysteinemia are folate and vita-
and D/P protein-bound homocysteine was analyzed addition- min B12 deficiency [7, 8]. Furthermore, a polymorphismally in a subgroup of 25 patients.
in the gene coding for the enzyme methylenetetrahy-Results. We observed a significant influence of plasma total
drofolate reductase (MTHFR 677C.T) has been dem-homocysteine concentrations (P 5 0.0001) of the daily dialysate
effluent volume (P 5 0.0221) and of the D/P creatinine (P 5 onstrated to aggravate hyperhomocysteinemia in patients
0.0132) on peritoneal elimination of total homocysteine. The maintained on chronic hemodialysis treatment [9]. Simi-
daily peritoneal excretion of total homocysteine was 38.94 6
larly, the major determinants of hyperhomocysteinemia20.82 mmol (5.27 6 2.81 mg). There was a positive linear associa-
in peritoneal dialysis patients are homozygosity for thetion of the daily total homocysteine elimination with plasma total
homocysteine concentrations (P 5 0.0001). A significant linear (677C.T) polymorphism in the MTHFR gene along
correlation was observed between D/P creatinine and D/P total with folate status and vitamin B12 plasma levels [10].
homocysteine (P 5 0.0001), D/P free homocysteine (P 5 Lowering elevated total homocysteine plasma levels
0.0001), as well as D/P protein-bound homocysteine (P 5 0.0001).
is suggested to have beneficial effects on cardiovascularConclusions. The peritoneal elimination of total homocys-
disease morbidity and mortality in renal failure patients.teine primarily depends on the plasma total homocysteine con-
centration. Elevated total homocysteine plasma levels cannot Therefore, renal replacement therapy may be an impor-
be reduced efficiently by peritoneal dialysis. tant tool to attenuate hyperhomocysteinemia in these pa-
tients. Several studies have demonstrated that hemodialy-
sis treatment lowers increased total homocysteine plasma
An elevated total homocysteine plasma concentration, concentrations only transiently [6, 11–13]. Thus far, few
referred to as hyperhomocysteinemia, represents an in- data are available about homocysteine concentrations in
dependent risk factor for cardiovascular disease [1–3]. the dialysate [14]. No information is provided on the daily
elimination of homocysteine by peritoneal dialysis and
its relationship to plasma total homocysteine concentra-Key words: peritoneal transport, CAPD, hyperhomocysteinemia, car-
tions [3]. In this study, we investigated the peritonealdiovascular disease, end-stage renal disease.
export of total homocysteine as well as the peritoneal
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Table 1. Characteristics of 39 continuous ambulatory peritoneal dialysis patients
Mean 6 sd Median Full range
Age years 52.1613.2 52.5 45.1
Sex female/male 19/20 — —
Duration of peritoneal dialysis years 1.261.0 0.89 3.78
Plasma tHcy concentration lmol/liter 22.9610.4 21.9 43.0
Plasma folate level nmol/liter 19.368.90 16.6 35.2
Plasma vitamin B12 level pmol/liter 304.86224.0 256.8 1191.6
Serum albumin g/liter 41.564.70 41.4 24.7
Peritoneal tHcy elimination lmol/24 hr 38.94620.82 32.34 114.84
D/P creatinine at 4 hours 0.63 60.11 0.63 0.49
High/high average transporters 16 (41%) — —
Low/low average transporters 23 (59%) — —
D/D0 glucose at 4 hours 0.37 60.08 0.38 0.38
D/P albumin at 4 hours 0.013 60.008 0.011 0.037
Dialysate volume liter/day 8.7762.53 8.35 11.7
Weekly Kt/V 2.3 60.4 2.28 1.83
Total creatinine clearance liter/week 75.3623.5 70.1 96.0
Residual renal clearance ml/min 3.5463.33 2.97 13.7
Abbreviations are: tHcy, total homocysteine; D/P, dialysate-to-plasma ratio; D/D0, ratio of dialysate glucose at 4 hours to dialysate glucose at 0 dwell time.
METHODS In a second set of experiments, the plasma and dialy-
sate concentrations of total, free, and protein-boundStudy population
homocysteine were simultaneously determined for anal-Thirty-nine CAPD patients (20 males, 19 females,
ysis of D/P ratios at four hours of dwell time in 25 ofmean age 52.1 6 13.2 years, mean duration of CAPD
the 39 CAPD patients. Linear associations between D/Ptreatment 1.2 6 1.0 years) with end-stage renal failure
creatinine at four hours and D/P total, free, and protein-treated at the peritoneal dialysis unit at the University
bound homocysteine were analyzed in these 25 patients.Hospital of Vienna were investigated. Patients with a
homozygous (677C.T) polymorphism in the MTHFR
Dialysis dose, residual renal function, and totalgene were excluded from this study, as this genetic variant
weekly clearanceis known to influence homocysteine plasma concentra-
Weekly dialysis dose (Kt/V) and creatinine clearancestions in renal failure patients [9, 10]. The characteristics
were calculated using the software PD Adequest (Baxterof the patients are depicted in Table 1. Dialysis treatment
Healthcare Corp., Deerfield, IL, USA). Each patient waswas initiated because of end-stage renal disease caused
by shrunken kidneys of unknown etiology (N 5 14), instructed to collect 24-hour dialysate and urine samples.
diabetic nephropathy (N 5 6), polycystic kidney disease One blood sample was taken at the day of dialysate and
(N 5 5), chronic glomerulonephritis (N 5 4), nephroscle- urine collection. The average of renal urea clearance and
rosis (N 5 4), chronic interstitial nephritis (N 5 4), and renal creatinine clearance was used to calculate residual
miscellaneous nephropathies (N 5 2). In 10 of the 39 renal clearance. The total weekly residual renal and peri-
patients, peritoneal dialysis was initiated because of sec- toneal creatinine clearance was related to 1.73 m2 of the
ondary graft failure. Only dialysate solutions containing body surface area.
lactate as a buffer and glucose as an osmotic agent were
used. The dialysate solutions contained neither amino Peritoneal equilibration test
acids nor glucose polymers. The glucose concentration The peritoneal equilibration test (PET) was per-
of the dialysate was adjusted to the clinical requirements
formed in all 39 CAPD patients as described by Twar-
of the patients. Thirteen of the 39 patients received a
dowski et al [15, 16]. The D/P creatinine at four hoursroutine oral vitamin supplementation of 0.18 mg of folate
was used to characterize peritoneal transport types. Low/per day. Written informed consent was given by all pa-
low average transporters were defined with a D/P creati-tients according to the Declaration of Helsinki and the
nine of 0.65 or less. High/high average transporters wereAustrian Law on Gene Technology. The influence of
defined with a D/P creatinine of more than 0.65 [16].total homocysteine, folate and vitamin B12 plasma con-
To investigate the relationship between peritonealcentrations, albumin serum levels, dialysate effluent vol-
transport of creatinine and homocysteine moieties, theume, effluent albumin, dialysate-to-plasma ratio (D/P)
D/P creatinine, total, free, and protein-bound homocys-creatinine at four hours, D/P albumin at four hours, ratio
teine at four hours were analyzed additionally in a secondof dialysate glucose at 4 hours to dialysate glucose at 0
set of experiments in 25 of the 39 patients. All D/Pdwell time (D/D0), sex, and age on the daily peritoneal
ratios were determined using 2.27% glucose dialysateelimination of total homocysteine was investigated in all
39 patients. solutions.
Vychytil et al: Peritoneal elimination of homocysteine moieties2056
Biochemical assays RESULTS
Citrated blood was collected for the determination of Plasma levels of the major determinants of
total and free homocysteine, folate and vitamin B12 lev- homocysteine concentrations
els, as well as for the analysis of the MTHFR alleles. The The mean total homocysteine plasma concentration,
samples were immediately placed on ice and centrifuged as well as the mean folate, vitamin B12, and albumin
within 60 minutes at 2000 g at 48C (20 min). Plasma plasma levels of all 39 CAPD patients is summarized in
aliquots were stored at –708C, whereas citrated whole Table 1.
blood was stored at –208C for isolation of DNA. Total
(5 free 1 protein-bound homocysteine moieties) plasma Peritoneal equilibration tests and determination of the
homocysteine levels (normal concentrations # 15 mmol/ adequacy of peritoneal dialysis
liter) and peritoneal effluent total homocysteine concen- The mean weekly Kt/V was 2.3 6 0.4. The mean total
trations were determined by automated high-perfor- weekly creatinine clearance was 75.3 6 23.5 liter, and
mance liquid chromatography (HPLC) with reversed- the mean residual renal clearance was 3.54 6 3.33 ml/
phase separation and fluorescence detection using a min. The average dialysate effluent volumes, the dialy-
modification of the method originally described by Araki sate albumin losses, as well as the results of the PETs,
and Sako [17]. Free homocysteine of the plasma and are shown in Table 1. The D/P creatinine at four hours
dialysate was determined following deproteinization. was 0.65 or less (low/low average transporters) in 23 of
Protein-bound homocysteine concentrations were calcu- the 39 patients (59%) and more than 0.65 (high/high
lated as the difference between total and free homocys- average transporters) in 16 patients (41%). The D/P
teine concentrations. The total amount of homocysteine creatinine, as well as D/P albumin, showed a negative
eliminated by the peritoneal route per day was calculated correlation with D/D0 glucose (r 5 –0.921, P 5 0.0001,using the molecular weight of homocysteine by the fol- and r 5 –0.440, P 5 0.005, respectively), whereas D/P
lowing formula: Total homocysteine effluent (mg/24 hr) 5 creatinine and D/P albumin were positively correlated
0.1352 3 (effluent volume, liter/day) 3 (total homocys- (r 5 0.487, P 5 0.002).
teine effluent, mmol/liter). Creatinine, glucose, and albu- Compared with patients with low/low average perito-
min concentrations were measured in all dialysates and
neal transport rates, high/high average transporters had
in the blood samples with an automated analyzer (Hi-
similar mean 24-hour dialysate effluent volumes (8.21 6tachi 747; Boehringer Mannheim, Mannheim, Germany).
2.86 vs. 9.24 6 2.16 liter, P 5 NS), a comparable weeklyPlasma folate (normal range of 3.4 to 38 nmol/liter) and
Kt/V (2.32 6 0.46 vs. 2.23 6 0.35, P 5 NS), a slightlyvitamin B12 (normal range of 118 to 720 pmol/liter) levels higher total weekly creatinine clearance (82.5 6 26.4 vs.were measured with a radioassay that allowed simultane-
69.2 6 19.3 liter, P 5 0.078), and a similar residual renalous determination of both vitamin concentrations in a
function (4.02 6 3.90 ml/min vs. 3.13 6 2.78 ml/min, P 5single reaction tube (SimulTRAC-SNB; Becton Dickin-
NS). Patients with a D/P creatinine of more than 0.65son, Ontario, Canada). Identification of the 677C.T
had significantly higher albumin losses into the dialysatetransition in the MTHFR gene was performed as de-
than low/low average transporters (6.72 6 1.48 g/24 hrscribed previously [18].
vs. 4.43 6 1.27 g/24 hr, P , 0.00001). The mean total
homocysteine plasma levels did not differ between theStatistical methods
two groups (high/high average transporters, 21.94 6Descriptive statistics included means 6 sd, medians,
10.68 mmol/liter, vs. low/low average transporters, 23.73 6and full ranges for continuous data and frequencies and
10.28 mmol/liter, P 5 NS).percentage for categorical data. Pearson’s correlation
was used to assess linear associations. To determine the
Peritoneal elimination of total homocysteinepredictors of peritoneal elimination of total homocys-
The total homocysteine concentration in the perito-teine, a general linear model (multiple stepwise regres-
neal effluent of 39 CAPD patients was 4.6 6 2.2 mmol/sion) was used, which included total homocysteine
liter (mean 6 sd; median, 4.1 mmol/liter; full range, 11.2plasma concentrations, folate, vitamin B12 and albumin
mmol/liter), corresponding to a daily peritoneal excretionlevels, age, sex, D/P creatinine, D/D0 glucose, D/P albu-
of 38.94 6 20.82 mmol (5.27 6 2.81 mg) of total homocys-min, effluent volume and effluent albumin as indepen-
teine. CAPD patients with a D/P creatinine of more thandent variables, and the daily amount of total homocys-
0.65 showed a slightly, but not significantly, higher dailyteine eliminated into the peritoneal dialysate as outcome
peritoneal total homocysteine excretion compared withvariable. Unpaired comparisons were performed by Stu-
those with a D/P creatinine of 0.65 or less of 41.61 6dent’s t-test. All calculations were performed at the Insti-
23.25 mmol (5.63 6 3.14 mg) versus 36.64 6 18.76 mmoltute of Medical Statistics at the University of Vienna
(4.96 6 2.53 mg). Multiple linear stepwise regressionusing the statistical software package SAS (SAS Institute
Inc., Cary, NC, USA). analysis revealed a significant influence of the plasma
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Table 2. Predictors of peritoneal total homocysteine elimination in the 25 patients and in the subgroups of low/low average
39 continuous ambulatory peritoneal dialysis patients
and high/high average transporters (D/P creatinine at 4
P (multiple stepwise hr # 0.65 vs. D/P creatinine . 0.65) is shown in Figure 2.
regression) High/high average transporters displayed a significantly
Plasma total homocysteine concentration 0.0001 higher D/P of total, free, and protein-bound homocys-
D/P creatinine at 4 hours 0.0132
teine compared with low/low average transporters.Daily effluent volume 0.0221
Plasma folate level NS In Table 4, the plasma and dialysate concentrations
Plasma vitamin B12 level NS of total, free, and protein-bound homocysteine, the D/P
Serum albumin level NS
total, free, and protein-bound homocysteine, as well asEffluent albumin NS
D/D0 glucose at 4 hours NS the percentage of free homocysteine in relationship to
D/P albumin at 4 hours NS total homocysteine in CAPD patients with serum albu-
Sex NS
min levels above and below the sample median are sum-Age NS
marized. Total homocysteine plasma concentrations
tended to be lower in patients with a serum albumin
concentration below the sample median of 40 g/liter (P 5
0.077; Table 4). By way of contrast, protein-bound homo-total homocysteine concentration (P 5 0.0001), the D/P
creatinine (P 5 0.0132), and the daily dialysate effluent cysteine in the plasma was significantly higher in patients
with serum albumin levels more than the median com-volume (P 5 0.0221) on the peritoneal elimination of
total homocysteine (Table 2). An increase of the total pared with those with serum albumin concentrations #
median, whereas free homocysteine levels in plasmaplasma homocysteine concentration of 10 mmol/liter re-
sulted in an estimated increase of the peritoneal total were comparable between the two groups. The fraction
of free homocysteine from total homocysteine in patientshomocysteine elimination of 12.59 mmol (1.7 mg) per
day. A higher daily peritoneal effluent volume of one with serum albumin levels # median was significantly
liter showed an estimated increase of 2.37 mmol (0.32 lower in the dialysate, but significantly higher in the
mg) of total homocysteine excreted peritoneally per day. plasma compared with patients showing albumin levels
A D/P creatinine increase of 0.01 led to an increase of above the sample median. Dialysate concentrations of
total homocysteine elimination of 0.52 mmol (0.07 mg) total, free, and protein-bound homocysteine did not dif-
per day. The other variables showed no significant influ- fer between the two subgroups according to the serum
ence on total homocysteine elimination (Table 2). albumin levels (Table 4). However, D/P total and D/P
There was a positive linear association (Pearson’s cor- protein-bound homocysteine were significantly higher in
relation) of daily total homocysteine elimination with patients with serum albumin levels # median.
plasma total homocysteine concentrations (r 5 0.631, P 5
0.0001) and the daily dialysate effluent volume (r 5 0.333,
DISCUSSIONP 5 0.038), whereas no linear relationship with D/P
This study demonstrates that the daily peritoneal elim-creatinine was observed (r 5 0.136, P 5 0.409).
ination of homocysteine in patients maintained on
Relationship between D/P creatinine and D/P total CAPD treatment primarily depends on total homocys-
homocysteine, D/P free homocysteine, and D/P teine plasma concentrations (P 5 0.0001). The daily peri-
protein-bound homocysteine in 25 CAPD patients toneal effluent volume and peritoneal transport charac-
teristics (D/P creatinine at 4 hr) showed a weaker, butThe mean plasma and dialysate concentrations of total
still significant influence (P 5 0.0221 and P 5 0.0132,homocysteine, free homocysteine, and protein-bound
respectively). An increase of the total plasma homocys-homocysteine, as well as the percentage of free homocys-
teine concentration of 10 mmol/liter resulted in an esti-teine in relation to total homocysteine in the plasma and
mated increase of peritoneal total homocysteine elimina-dialysate, are summarized in Table 3 with regard to the
tion of 12.59 mmol (1.7 mg) per day. A higher dailyperitoneal transporter status. Overall, there was no sig-
peritoneal effluent volume of one liter increased the esti-nificant difference in these parameters between high/
mated amount of total homocysteine excreted peritone-high average and low/low average transporters (Table
ally to 2.37 mmol (0.32 mg) per day. A D/P creatinine3). Free homocysteine amounted to 47.5% of the total
increase of 0.01 led to an increase of total homocysteinehomocysteine in the plasma and to 75.2% of the total
elimination of 0.52 mmol (0.07 mg) per day. In the sub-homocysteine in the dialysate. A significant positive cor-
group of 25 patients, the positive correlation of D/Prelation of the D/P of total, free, and protein-bound
creatinine with D/P free homocysteine was stronger thanhomocysteine with D/P creatinine was observed. The
the correlation with D/P total or D/P protein-boundmost significant linear association was found between D/P
homocysteine.creatinine and D/P free homocysteine (Fig. 1). The mean
D/P of total, free, and protein-bound homocysteine in Hyperhomocysteinemia is an established, important
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Table 3. Mean plasma and dialysate concentrations of total, free and protein-bound homocysteine and percentage of free homocysteine in
dialysate and plasma samples obtained from peritoneal equilibration tests of 25 CAPD patients
High/high Low/low
average average
All
patients transporters
N 25 10 15
Plasma tHcy lmol/liter 24.34611.8 22.28 611.44 25.86 612.22
Plasma fHcy lmol/liter 11.3265.14 10.72 64.92 11.73 65.41
Plasma pbHcy lmol/liter 13.1066.93 11.56 66.84 14.13 67.03
Percentage of plasma fHcy 47.5 66.3 49.5 66.7 46.1 65.9
Dialysate tHcy lmol/liter 7.5963.94 8.69 63.59 6.86 64.11
Dialysate fHcy lmol/liter 5.7262.98 6.43 62.65 5.25 63.19
Dialysate pbHcy lmol/liter 1.8761.01 2.26 61.02 1.61 60.94
Percentage of dialysate fHcy 75.2 64.4 73.8 63.3 76.2 64.8
Abbreviations are: tHcy, total homocysteine; fHcy, free homocysteine; pbHcy, protein-bound homocysteine.
cardiovascular risk factor in end-stage renal disease pa- teine removed by peritoneal dialysis suggests that other
factors, which are probably influencing dialysate homo-tients [7, 8]. Strategies to improve the disturbed homo-
cysteine metabolism and thus to lower elevated total cysteine concentrations, such as intraperitoneal produc-
tion, are neglectible. In another study, a positive correla-homocysteine concentrations may rely on either vitamin
intervention or the removal of total homocysteine by tion of plasma total homocysteine with dialysate total
homocysteine concentration was observed [14]. Thus,renal replacement therapy. In hemodialysis patients and
peritoneal dialysis patients, folate intervention has been our data support the concept that plasma total homocys-
teine is the major source of peritoneal total homocysteinedemonstrated to lower total homocysteine levels in most,
but not all, treated patients [19, 20]. By contrast, hemodi- elimination. In this context, an analysis with regard to
the daily homocysteine production would be valuable toalysis treatment has been shown to only transiently re-
duce the elevated plasma homocysteine concentration estimate the relative quantity of peritoneal total homo-
cysteine elimination. In a previous study, the dailyin some patients [6, 11–13]. Kidney transplantation is
able to improve hyperhomocysteinemia rapidly [21], but amount of homocysteine moieties involved in remethyla-
tion in healthy male subjects on a standard diet wasin many kidney transplant patients with excellent graft
function, hyperhomocysteinemia persists depending on approximated to be 9.7 mmol, which was cycled 1.9 times
a day, resulting in approximately 18.4 mmol (2488 mg)the MTHFR genotype [22] or a disturbance in the trans-
sulfuration pathway of homocysteine conversion [23]. of homocysteine available per day [25]. Thus, the daily
peritoneal elimination of total homocysteine may onlyPrevious studies demonstrated the presence of higher
total homocysteine plasma concentrations in hemodialy- represent approximately 0.21% of the daily production
in healthy individuals, which is comparable to the mini-sis patients compared with peritoneal dialysis patients
[5, 9, 10, 14, 24], raising the question of the factors de- mal urinary excretion of normal subjects [26].
The peritoneal effluent volume also had a significanttermining total homocysteine concentrations in patients
on different forms of renal replacement therapy. A re- influence on and correlated positively with the daily peri-
toneal elimination of total homocysteine. However, thecent study of 154 peritoneal dialysis patients revealed
that the MTHFR genotype, folate, and vitamin B12 levels interpretation of this relationship is hindered by the pres-
ence of mathematical coupling in this analysis (becauseare the major determinants of hyperhomocysteinemia in
this particular patient group, whereas Kt/V, residual re- the effluent volume is correlated with the product of
effluent volume 3 effluent total homocysteine). An esti-nal function, total weekly creatinine clearance, age, sex,
mode of peritoneal dialysis treatment, and low-dose vita- mated increase of total homocysteine elimination of 2.37
mmol (0.32 mg) per liter of peritoneal effluent suggestsmin intake had no influence [10]. In hemodialysis pa-
tients, plasma folate and albumin levels, as well as that an increase of the daily dialysate volume may be able
to enhance slightly the peritoneal elimination of totalthe MTHFR (677C.T) gene polymorphism, influenced
plasma total homocysteine concentrations [9]. homocysteine without a major lowering effect on plasma
total homocysteine concentrations. In a separate study,In this study, we demonstrate that the peritoneal elimi-
nation of total homocysteine is approximately 39 mmol we have also measured total homocysteine concentra-
tions in the effluent of patients on automated peritoneal(5.3 mg) per day in CAPD patients and particularly de-
pends on plasma homocysteine concentrations. The dialysis (APD). However, no effluent total homocysteine
was detectable in 9 of 17 APD patients investigated (datastrong positive correlation of total homocysteine plasma
concentrations with the daily amount of total homocys- not shown), in contrast to 1 of 39 CAPD patients. This
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Fig. 2. D/P total homocysteine (tHcy), D/P free homocysteine (fHcy),
as well as D/P protein-bound homocysteine (pbHcy) at four hours of
dwell time in 25 CAPD patients ( ), including 15 high/high average
transporters (j) and 10 low/low average transporters (h). *P 5 0.0001
vs. high/high average transporters. **P 5 0.001 vs. high/high average
transporters.
Table 4. Mean plasma and dialysate concentrations and D/P total,
free and protein-bound homocysteine, and percentage of free
homocysteine in dialysate and plasma samples of patients with
a serum albumin below and above the sample median
Serum albumin Serum albumin
#median .median P
N 13 12
Plasma tHcy lmol/liter 20.42613.56 28.77 68.0 0.077
Plasma fHcy lmol/liter 10.2366.07 12.51 63.82 NS
Plasma pbHcy lmol/liter 10.1967.75 16.26 64.29 0.025
Percentage of plasma fHcy 51.3 66.4 43.3 62.5 0.0005
Dialysate tHcy lmol/liter 7.4964.52 7.70 63.39 NS
Dialysate fHcy lmol/liter 5.5363.37 5.93 62.63 NS
Dialysate pbHcy lmol/liter 1.9661.20 1.77 60.79 NS
Percentage of dialysate fHcy 73.4 63.8 77.2 64.2 0.026
D/P creatinine at 4 hours 0.69 60.09 0.59 60.12 0.029
D/P albumin at 4 hours 0.009 60.004 0.008 60.003 NS
D/P tHcy at 4 hours 0.38 60.09 0.26 60.08 0.001
D/P fHcy at 4 hours 0.55 60.11 0.47 60.13 0.086
Fig. 1. Relationship between the dialysate-to-plasma ratio (D/P) of D/P pbHcy at 4 hours 0.22 60.07 0.11 60.04 0.0001
creatinine and D/P total homocysteine (B; tHcy; r 5 0.857, P 5 0.0001),
Abbreviations are: tHcy, total homocysteine; fHcy, free homocysteine; pbHcy,D/P free homocysteine (A; fHcy; r 5 0.907, P 5 0.0001), as well as D/P
protein-bound homocysteine.protein-bound homocysteine (C; pbHcy; r 5 0.704, P 5 0.0001) in 25
CAPD patients.
tration is the major determinant of peritoneal total homo-
cysteine elimination.observation is most likely due to the diluting effect of
Among our 39 CAPD patients, 23 patients presented
the higher effluent volumes of APD patients compared with low/low average transport rates, whereas 16 patients
with CAPD patients, resulting in peritoneal effluent total were high/high average transporters. Not unexpectedly,
homocysteine concentrations that were below the detec- the D/P creatinine, as well as the D/P albumin, showed
tion sensitivity of our HPLC method. Nevertheless, one a negative correlation with D/D0 glucose, whereas D/P
of the patients on APD treatment who was homozygous creatinine and D/P albumin were correlated positively,
for the 677C.T allele of the MTHFR gene had a plasma which is in line with previous observations [15, 27]. By
total homocysteine concentration of 104.1 mmol/liter and contrast, a significant difference in peritoneal albumin
showed a daily peritoneal elimination of total homocys- elimination between high/high average and low/low av-
teine of 192.6 mmol (26 mg). This observation supports erage transporters was observed. This finding of a higher
peritoneal albumin excretion in high/high average trans-our finding that the plasma total homocysteine concen-
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porters suggests that this patient group also shows a depends on the plasma total homocysteine concentra-
higher peritoneal excretion of protein-bound homocys- tion, whereas the daily effluent volume and the trans-
teine. However, only a slightly increased, but not signifi- porter status have only little influence. Hyperhomocys-
cantly higher, daily mean total homocysteine elimination teinemia in end-stage renal disease patients is the result
was observed in high/high average transporters. The lat- of the impaired remethylation and transsulfuration path-
ter patients also showed a trend toward a higher total ways of the homocysteine metabolism. Elimination of
weekly creatinine clearance compared with low/low av- total homocysteine by the peritoneal route does not suf-
erage transporters. Nevertheless, the peritoneal trans- fice to improve hyperhomocysteinemia in CAPD pa-
porter status significantly influenced total homocysteine tients. Plasma total homocysteine-lowering interventions
elimination in our linear regression model but showed should therefore focus on folic acid and vitamin therapy
no linear association with the degree of daily peritoneal to improve the conversion of homocysteine in these pa-
total homocysteine elimination. tients, in an effort to reduce vascular disease morbidity
In a subgroup of 25 CAPD patients, the D/P creatinine and mortality.
was correlated with D/P total homocysteine, D/P free
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